2,364 reports of this reaction
18.5% of all ICATIBANT ACETATE reports
#1 most reported adverse reaction
HEREDITARY ANGIOEDEMA is the #1 most commonly reported adverse reaction for ICATIBANT ACETATE, manufactured by Takeda Pharmaceuticals America, Inc.. There are 2,364 FDA adverse event reports linking ICATIBANT ACETATE to HEREDITARY ANGIOEDEMA. This represents approximately 18.5% of all 12,796 adverse event reports for this drug.
Patients taking ICATIBANT ACETATE who experience hereditary angioedema should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEREDITARY ANGIOEDEMA is a frequently reported adverse event for ICATIBANT ACETATE, accounting for a significant proportion of all reports.
In addition to hereditary angioedema, the following adverse reactions have been reported for ICATIBANT ACETATE:
The following drugs have also been linked to hereditary angioedema in FDA adverse event reports:
HEREDITARY ANGIOEDEMA has been reported as an adverse event in 2,364 FDA reports for ICATIBANT ACETATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEREDITARY ANGIOEDEMA accounts for approximately 18.5% of all adverse event reports for ICATIBANT ACETATE, making it one of the most commonly reported side effect.
If you experience hereditary angioedema while taking ICATIBANT ACETATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.